WalletHub: 5 best chip and pin credit cards
In a WalletHub story identifying the best chip and pin credit cards for consumers, Cincinnati Law’s Susan Stephan, Director of the MLS Program, provided expert commentary about the adoption of chip and pin credit cards in the United States.
“The adoption of chip-and-PIN credit cards has been relatively slow in the U.S., particularly compared to other countries including Canada, Japan, and - notably - the European Union,” said Stephan. “Although more secure than chip and signature cards that still dominate the U.S., upgrading payment systems to support chip-and-PIN can be expensive for businesses, and there has not yet been a significant consumer push for the technology.”
A chip and PIN credit card is a card that contains a small computer chip and gives users a 4-digit personal identification number (PIN) to enter when making purchases. Chip and PIN credit cards provide improved security compared to chip and signature cards and magnetic stripe cards.
In the WalletHub article, Stephan also addressed the biggest misconceptions about “chip” cards, using the cards internationally, and the safety of chip and pin cards versus other types.
Read Stephan’s full interview: "5 Best Chip and Pin Credit Cards".
Lead photo: istockphoto.com
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.